F024 A Primer and Practical Approach to Cancer Checkpoint Inhibitors for the Dermatologist
DESCRIPTION
Novel cancer immunotherapies, specifically immune checkpoint inhibitors (CPIs), have recently emerged, redefining treatment paradigms in oncology. However, CPIs present significant complications, with pruritus and skin-related toxicities being among the most common adverse effects. These issues necessitate a new skill set for practitioners caring for cancer patients receiving this class of medication. This session aims to enhance dermatology practitioners' knowledge of the underlying science of cancer immunotherapies, common adverse events and skin-related toxicities, and current NCCN guidelines alongside other management strategies for CPI-induced adverse events.
LEARNING OBJECTIVES
Summarize the science of the novel cancer immunotherapies called checkpoint inhibitors and their mechanisms of actions.
Discuss the current FDA-approved checkpoint inhibitor therapies and their uses in dermatology along with associated adverse events and dermatology-related toxicities.
Apply the NCCN guideline recommendations for the management of checkpoint inhibitor-related skin toxicities.
SCHEDULE
9:00 AM
Introduction
Oliver J. Wisco, DO, FAAD
9:05 AM
Overview of FDA-Approved Checkpoint Inhibitors with a Focus on NCCN Guideline Skin Cancer Indications and Mechanism of Action for Each Class
Oliver J. Wisco, DO, FAAD
9:20 AM
Q&A with Dr. Wisco
Oliver J. Wisco, DO, FAAD
9:25 AM
Dermatologic CPI Neoadjuvant Use
Michael Tetzlaff, MD, PhD
9:40 AM
Q&A with Dr. Tetzlaff
Michael Tetzlaff, MD, PhD
9:45 AM
Review of NCCN guidelines for Managing CPI ADRs and Dermatology-Related Toxicities
Anisha Patel, MD, FAAD
10:00 AM
Q&A with Dr. Patel
Anisha Patel, MD, FAAD
10:05 AM
CPI Toxicity Incidence Overall and Correlation with Response with Concerns in Patients with Pre-Existing Skin Disease
Noah Io Hornick, MD, PhD, FAAD
10:20 AM
Q&A with Dr. Hornick
Noah Io Hornick, MD, PhD, FAAD
10:25 AM
Panel Discussion on Cutaneous Oncology Cases and Management of Checkpoint Inhibitor induced Dermatologic Toxicities
DIRECTOR
Oliver J. Wisco, DO, FAAD
SPEAKERS
Noah Io Hornick, MD, PhD, FAAD
Anisha Patel, MD, FAAD
UT MD Anderson Cancer Center
Michael Tetzlaff, MD, PhD
DISCLOSURES
Noah Io Hornick, MD, PhD, FAAD
HMP Education – Speaker(Honoraria); Regeneron – Advisory Board(Fees); Shook Hardy & Bacon – Consultant (1099 relationship)(Fees); Therakos, Inc. – Data Safety Monitoring Board(Fees);
Anisha Patel, MD, FAAD
Asymmetric Therapeutics, LLC – Consultant (1099 relationship)(Fees); EMD Serono – Advisory Board(Fees); Erasca – Consultant (1099 relationship)(Fees); FBIO Acquisition Corp LII – Consultant (1099 relationship)(Stock); Hoth Therapeutics – Investigator(Grants/Research Funding); Janssen Scientific Affairs, LLC – Consultant (1099 relationship)(Fees); Lutris – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Revolution Medicines – Advisory Board(Fees); Roche Pharma – Consultant (1099 relationship)(Fees); SynOx Therapeutics – Consultant (1099 relationship)(Fees); UpToDate, Inc – Other(Patent royalties or other compensation for Intellectual Property Rights);
Michael Tetzlaff, MD, PhD
Merck – Other(Fees); Philogen S.p.A. – Advisory Board(Fees); Regeneron – Advisory Board(Honoraria);
Oliver J. Wisco, DO, FAAD
Castle Biosciences – Investigator(Fees); Natera – Advisory Board(Fees); Regeneron – Consultant (1099 relationship)(Fees), Investigator(Fees);